US2019350897A1PendingUtilityA1
Escalating dosing regimen for effecting weight loss and treating obesity
Est. expiryJun 9, 2028(~1.9 yrs left)· nominal 20-yr term from priority
A61P 3/06A61P 9/12A61P 43/00A61P 9/10A61P 3/10A61P 35/00A61P 25/00A61P 25/20A61P 3/04A61P 25/06A61P 31/04A61P 25/02A61P 11/06A61P 11/00A61P 19/06A61P 1/08A61P 21/00A61P 15/00A61P 19/02A61K 9/4866A61K 31/7048A61K 9/1629A61K 9/5026A61K 9/1623A61K 9/5047A61K 31/135A61K 9/5073A61K 9/5084A61K 31/137A61K 31/35A61K 31/00A61K 9/167A61K 31/357A61K 9/1676A61K 9/5042A61K 47/38A61K 9/20
70
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention is drawn to novel topiramate compositions as well as methods for effecting weight loss, e.g., in the treatment of obesity and related conditions, including conditions associated with and/or caused by obesity per se. The present invention features an escalating dosing regimen adapted for the administration of topiramate and optionally a sympathomimetic agent such as phentermine or bupropion, in the treatment of obesity and related conditions.
Claims
exact text as granted — not AI-modified1 . A controlled release composition for treating obesity, diabetes, sleep apnea, or a related condition in a subject comprising:
an effective amount of topiramate and phentermine.
2 . A method for effecting weight loss in a subject, comprising administering to the subject continually over a significant period of time a daily dose of phentermine in combination therewith a daily dose of topiramate selected to prevent the loss of effectiveness of phentermine alone.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.